SEARCH   
 
Media Center
Chairman Jiang awards for national excellent science workers
26.07.2016 Hits: Large In Small


CHONGQING, May 16th 2016, Monday —Chinese Anti-tuberculosis Association annual national academic conference 2016 was held in Zhuhai Guangdong Province during April 27th-28th. Over 2000 representatives, experts and industry insiders both home and abroad attended the conference.

As the main sponsor, Mr.Jiang Rensheng, Chairman of Zhifei attended the conference and awarded for the first term of National Excellent Science Workers During the conference, Professor Xu Miao from National Institutes for Food and Drug Control (NIFDC) detailed the TB products---Recombinant mycobacterium tuberculosis ESAT6 - CFP10 allergen (“ESAT6 - CFP10 allergen”) and Vaccae® developed by Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., In his speech titled The Screening of LTBI and Immunoprophylaxis Research. Results from phaseⅡa/Ⅱb clinical trials suggests that ESAT6 - CFP10 allergen showed high consistency in both negative and positive coincidence rate with T-SPOT diagnostic test. Currently, ESAT6 - CFP10 allergen has entered phase Ⅲ clinical trial and the site work of Vaccae’s phase Ⅲ clinical trial is expected to be completed in the first half of 2016.
 
About Zhifei
 

Zhifei, a leading vaccine enterprise in China based on research, development, manufacturing and marketing, is committed to improving children‘s physical quality by sparing no efforts to supply innovative vaccines with high quality and low price for society under the principle of "social benefits first, economic profits second". It has four wholly-owned subsidiaries---Beijing Lvzhu Biopharmaceutical Co., Ltd., Anhui Longcom Biopharmaceutical Co., Ltd., Chongqing Zhiren Biotechnology Co., Ltd. and Zhifei (HONG KONG) Ltd. and one share-holding company---Chongqing Zhirui Investment Co., Ltd. For further information, please visit http://www.zhifeishengwu.com.